 |
인쇄하기
취소
|
Green Cross, MacroGenics sign exclusive license agreement to develop and commercialize Herceptin Bio
Green Cross Corporation and US-based MacroGenics Inc. announced on July 8 an agreement to grant Green Cross exclusive rights to develop and commercialize MGAH22, a next-generation and Fc-optimized mAB that targets HER2.
Green Cross plans to develop MGAH22 for the treatment of various cancers including breast cancer.
Under the terms of the agreement, MacroGenics granted Green Cross exclus...
Green Cross plans to develop MGAH22 for the treatment of various cancers including breast cancer.
Under the terms of the agreement, MacroGenics granted Green Cross exclus...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.